Get the Stockscreener App
1.365
0.83%
-0.015
Actinium Pharmaceuticals Inc stock is traded at $1.365, with a volume of 210.27K.
It is down -0.83% in the last 24 hours and down -13.39% over the past month.
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for patients with cancers lacking effective treatment options. Its lead product candidate is Iomab-B that is in Phase III clinical studies for myeloablation and conditioning of the bone marrow prior to a bone marrow transplant for patients with relapsed or refractory acute myeloid leukemia (AML) age 55 and older. The company is also developing Actimab-A, which is in Phase II clinical trials for the treatment of patients newly diagnosed with AML over the age of 60, as well as in Phase I clinical trials in combination with CLAG-M for patients with relapsed or refractory AML; and Actimab-M that is in Phase I clinical trials for patients with refractory multiple myeloma. Actinium Pharmaceutical, Inc. was founded in 2000 and is based in New York, New York.
See More
Previous Close:
$1.38
Open:
$1.35
24h Volume:
210.27K
Relative Volume:
1.15
Market Cap:
$42.58M
Revenue:
$81,000
Net Income/Loss:
$-41.04M
P/E Ratio:
-1.0365
EPS:
-1.3169
Net Cash Flow:
$-30.69M
1W Performance:
-7.53%
1M Performance:
-13.39%
6M Performance:
-11.71%
1Y Performance:
-22.25%
1-Day Range:
$1.33
$1.40
1-Week Range:
$1.33
$1.48
52-Week Range:
$1.06
$2.41
Actinium Pharmaceuticals Inc Stock (ATNM) Company Profile
Name
Actinium Pharmaceuticals Inc
Sector
Industry
Phone
646-767-3870
Address
275 Madison Avenue, 7th Floor, New York, NY
Compare ATNM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATNM
Actinium Pharmaceuticals Inc
|
1.365 | 43.05M | 81,000 | -41.04M | -30.69M | -1.3169 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.78 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.49 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.43 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.67 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.44 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Actinium Pharmaceuticals Inc Stock (ATNM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-07-24 | Downgrade | B. Riley Securities | Buy → Neutral |
| May-14-24 | Initiated | Stephens | Overweight |
| Sep-06-23 | Initiated | HSBC Securities | Buy |
| Feb-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-08-22 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-25-22 | Initiated | B. Riley Securities | Buy |
| Nov-05-20 | Initiated | Alliance Global Partners | Buy |
| Dec-06-17 | Initiated | B. Riley FBR, Inc. | Buy |
| Oct-23-17 | Resumed | ROTH Capital | Buy |
| Sep-14-17 | Initiated | Maxim Group | Buy |
| Aug-25-16 | Initiated | ROTH Capital | Buy |
| Feb-29-16 | Initiated | H.C. Wainwright | Buy |
| Oct-15-15 | Initiated | FBR Capital | Outperform |
| Oct-01-14 | Initiated | MLV & Co | Buy |
| Jul-22-14 | Initiated | Canaccord Genuity | Buy |
View All
Actinium Pharmaceuticals Inc Stock (ATNM) Latest News
Is Actinium Pharmaceuticals Inc. (7AY1) stock a momentum leaderJuly 2025 Macro Moves & Low Risk High Win Rate Stock Picks - newser.com
Actinium Pharmaceuticals, Inc. to Highlight ATNM-400 Data in Hormone-Resistant and HER2-Resistant Breast Cancer at the 2025 San Antonio Breast Cancer Symposium, Expanding Pan-Tumor Profile Across Three Solid Tumor Indications - WV News
Can you recover from losses in Actinium Pharmaceuticals Inc.Watch List & Technical Buy Zone Confirmation - newser.com
Identifying reversal signals in Actinium Pharmaceuticals Inc.Weekly Investment Report & Community Trade Idea Sharing - newser.com
Why retail traders accumulate Actinium Pharmaceuticals Inc. (Delaware) stockJuly 2025 PostEarnings & Stepwise Swing Trade Plans - newser.com
What momentum shifts mean for Actinium Pharmaceuticals Inc.2025 Top Gainers & Reliable Price Breakout Signals - newser.com
Will Actinium Pharmaceuticals Inc. (7AY1) stock outperform foreign stocks2025 Bull vs Bear & AI Powered Market Trend Analysis - newser.com
How Actinium Pharmaceuticals Inc. (Delaware) stock expands through international marketsTrade Signal Summary & Verified Stock Trade Ideas - newser.com
How moving averages guide Actinium Pharmaceuticals Inc. tradingWeekly Profit Summary & Weekly High Potential Stock Alerts - newser.com
Is Actinium Pharmaceuticals Inc. stock ready for a breakoutJuly 2025 Fed Impact & Community Verified Trade Signals - newser.com
Actinium Pharmaceuticals, Inc. to Participate in the Stephens Biotechnology Virtual Fireside Chat Conference - PR Newswire
How supply shortages influence Actinium Pharmaceuticals Inc. (Delaware) stockPortfolio Gains Report & Weekly Market Pulse Alerts - newser.com
Is Actinium Pharmaceuticals Inc. stock a smart buy before Fed meetingProduct Launch & Fast Entry Momentum Alerts - newser.com
How Actinium Pharmaceuticals Inc. stock performs in rate cut cycles2025 Trade Ideas & Accurate Buy Signal Notifications - newser.com
Is Actinium Pharmaceuticals Inc. stock entering bullish territoryJuly 2025 Closing Moves & Stepwise Trade Execution Plans - newser.com
How Actinium Pharmaceuticals Inc. (Delaware) stock stacks up against competitors2025 Year in Review & Low Risk High Reward Trade Ideas - newser.com
Has Actinium Pharmaceuticals Inc. found a price floorIndex Update & AI Driven Stock Reports - newser.com
Why Actinium Pharmaceuticals Inc. (Delaware) stock stays undervaluedMarket Volume Summary & AI Based Buy and Sell Signals - newser.com
How Actinium Pharmaceuticals Inc. (Delaware) stock responds to bond marketJuly 2025 Volume & Fast Moving Market Watchlists - newser.com
Will Actinium Pharmaceuticals Inc. (7AY1) stock gain from lower interest ratesQuarterly Market Summary & Community Consensus Trade Alerts - newser.com
Published on: 2025-10-31 04:06:04 - newser.com
Is Actinium Pharmaceuticals Inc. (Delaware) stock a buy on weaknessWeekly Risk Report & AI Powered Buy and Sell Recommendations - newser.com
Actinium Pharmaceuticals Inc Stock (ATNM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.68%
0.49%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):